Browse by author
Lookup NU author(s): Dr Deborah Stocken
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Adenocarcinoma of the oesophagus is a systemic disease at presentation in the majority of patients. This article analyses the impact of preoperative chemotherapy on a cohort of 68 patients. From 1990 to 1996, 68 patients with potentially operable adenocarcinoma of the oesophagus were entered into three sequential Phase II trials of neoadjuvant chemotherapy with cisplatin/mitomycin C/ifosfamide, cisplatin/5-fluorouracil (5-FU) and mitomycin C/cisplatin/5-FU. Twenty-four (35%) patients had a radiological (4 complete; 20 partial) response to chemotherapy, and 52 (76%) went on to have the primary tumour resected. There was only one pathological complete responder. The overall median survival was 13 months (95% confidence interval (CI) 9–16). Survival for the 28 N0 patients was 34 months (95% CI 14–60). The pattern of failure for resected patients was predominantly systemic (16/17). These results indicate that neoadjuvant chemotherapy followed by surgery for adenocarcinoma of the oesophagus achieves excellent local control. The dominance, however, of distant recurrence after surgery underlines the fact that, in the majority of patients, the only hope of improving results in the future is to develop better systemic therapies.
Author(s): Archer VR, Mulholland PJ, Stocken DD, Darnton SJ, Ferry DR
Publication type: Article
Publication status: Published
Journal: Clinical Oncology
Year: 2001
Volume: 13
Issue: 3
Pages: 164-169
ISSN (print): 0936-6555
ISSN (electronic): 1433-2981
Publisher: W.B. Saunders Co. Ltd.
URL: http://dx.doi.org/10.1053/clon.2001.9246
DOI: 10.1053/clon.2001.9246
Altmetrics provided by Altmetric
